SecBot SecBot
SECBOTREPLAY Home › Report › CRVS

CRVS · Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M…

Corvus Pharmaceuticals, Inc. · 8-K filed May 7, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 7, 2026 at 16:01 ET

Corvus Pharmaceuticals reported Q1 2026 net loss of $13.7M ($0.15/share), slightly missing consensus of $0.14 loss. The miss is marginal and overshadowed by positive pipeline progress: soquelitinib Phase 2 AD trial initiation, ongoing Phase 3 PTCL enrollment, and upcoming SID data presentation on May 14.

  • Net loss per share $0.15 vs consensus $0.14 (7.1% miss)
  • Cash, cash equivalents and marketable securities $236.7M as of March 31, 2026
  • Phase 2 atopic dermatitis trial initiated in Q1 2026
  • Registrational Phase 3 PTCL trial enrollment continues

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access